Molecular biomarkers for aflatoxins: From adducts to gene mutations to human liver cancer

Canadian Journal of Physiology and Pharmacology

Volumn 74, Issue 2, 1996, Pages 203-209

  Groopman, John D ^a   Wang, Jia Sheng ^a   Scholl, Peter ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

aflatoxin; dosimetry; environmental cancer; epidemiology; liver cancer; molecular biomarkers

Indexed keywords

AFLATOXIN;

CONFERENCE PAPER; ETIOLOGY; GENE MUTATION; HUMAN; LIVER CANCER; PRIORITY JOURNAL;

EID: 0029882109     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y96-009     Document Type: Conference Paper

References (40)

1. Aguilar, F., Hussain, S.P., and Cerutti, P. 1993. Aflatoxin B1 induces the transversion of G → T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 90: 8586-8590.
2. Aguilar, F., Harris, C.C., Sun, T., Hollstein, M., and Cerutti, P. 1994. Geographic variation of p53 mutational profile in nonmalignant human liver. Science (Washington, D.C.), 264: 1317-1319.
3. Autrup, H., Bradley, K.A., Shamsuddin, A.K.M., Wakhisi, J., and Wasunna, A. 1983. Detection of putative adduct with fluorescence characteristics identical to 2,3-dihydro-2-(7′-guanyl)-3-hydroxyaflatoxin B1 in human urine collected in Murang'a district, Kenya. Carcinogenesis, 4(9): 1193-1195.
4. 1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res. 47: 3430-3433.
5. 1-treated rats. Cancer Res. 41: 650-654.
6. Bressac, B., Kew, M., Wands, J., and Ozturk, M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature (London), 350: 429-431.
7. Bulatao-Jayme, J., Almero, E.M., Castro, C.A., Jardeleza, T.R., and Salamat, L. 1982. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int. J. Epidemiol. 11(2): 112-119.
8. Campbell, T.C., Chen, J., Liu, C., Li. J., and Parpia, B. 1990. Non-association of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. Cancer Res. 50: 6881-6893.
9. Cerutti, P., Hussain, P., Pourzand, C., and Aguilar, F. 1994. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res. 54: 1934s-1938s.
10. Coursaget, P., Depril, N., Chabaud, M., Nandi, R., Mayelo, V., LeCann, P., and Yvonnet, B. 1993. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br. J. Cancer, 67: 1395-1397.
11. Eaton, D.L., and Groopman, J.D. (Editors). 1994. The toxicology of aflatoxins: human health, veterinary and agricultural significance. Academic Press, New York.
12. 1 in vitro. Proc. Natl. Acad. Sci. U.S.A. 74: 1870-1874.
13. 1. Proc. Natl. Acad. Sci. U.S.A. 80: 2695-2698.
14. Fujimoto, Y., Hampton, L.L., Wirth, P.J., Wang, N.J., Xie, J.P., and Thorgeirsson, S.S. 1994. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res. 54: 281-285.
15. 1. Carcinogenesis, 9: 1323-1325.
16. Greenblatt, M.S., Bennett, W.P., Hollstein, M., and Harris, C.C. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
17. Groopman, J.D., Zhu, J., Donahue, P.R., Pikul, A., Zhang, L.-S., Chen, J.-S., and Wogan, G.N. 1992a. Molecular dosimetry of urinary aflatoxin DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res. 52: 45-51.
18. 7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiology, Biomarkers and Prevention, 1: 221-228.
19. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. 1991. p53 mutations in human cancers. Science (Washington, D.C.), 253: 49-53.
20. Hsu, I.C., Metcalf, R.A., Sun, T., Wesh, J.A., Wang, N.J., and Harris, C.C. 1991. Mutational hotspot in the p53 gene in human hepatocellualr carcinomas. Nature (London), 350: 427-428.
21. IARC (International Agency for Research on Cancer). 1993. Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycoloxins. IARC Monogr. Eval. Carcinog. Risk Chem. Humans, 56: 1-599.
22. Li, D., Cao, Y., He, L., Wang, N.J., and Gu, J. 1993. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis, 14: 169-173.
23. Lippman, S.M., Lee, J.S., Lotan, R., Hittleman, W., Wargovich, M.J., and Hong, W.K. 1990. Biomarkers as intermediate end points in chemoprevention trials. J. Natl. Cancer Inst. 82: 555-562.
24. McGlynn, K.A., Rosvold, E.A., Lustbader, E.D., Hu, Y., Clapper, M.L., Zhou, T., Wild, C.P., Xia, X.L., Baffoe-Bonnie, A., Ofori-Adjei, D., and London, T. 1995. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. U.S.A. 92(6): 2384-2387.
25. National Cancer Office of the Ministry of Public Health, P.R.C. 1980. Studies on mortality rates of cancer in China. People's Publishing House, Beijing.
26. Ng, I.O., Srivastava, G., Chung, L.P., Tsang, S.W., and Ng, M.M. 1994. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer, 74: 30-37.
27. Ozturk, M. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 338: 1356-1359.
28. Peers, F., Bosch, X., Kaldor, J., Linsell, A., and Pluijmen, M. 1987. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int. J. Cancer, 39: 545-553.
29. Puisieux, A., Lim, S., Groopman, J.D., and Ozturk, M. 1991. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51: 6185-6189.
30. Qian, G.-S., Yu, M.C., Ross, R., Yuan, J.-M., Gao, Y.-T., Wogan, G.N., and Groopman, J.D. 1994. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, P.R.C. Cancer Epidemiology, Biomarkers and Prevention, 3: 3-11.
31. Ross, R., Yuan, J.-M., Yu, M., Wogan, G.N. Qian, G.-S., Tu, J.-T., Groopman, J.D., Gao, Y.-T., and Henderson, B.E. 1992. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339: 943-946.
32. 1 in vivo in rats. Carcinogenesis, 8: 819-824.
33. Srivatanakul, P., Parkin, D.M., Khlat, M., Chenvidhya, D., Chotiwan, P., Insiripong, S., L'Abbé, K.A., and Wild, C.P. 1991. Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma. Int. J. Cancer, 48: 329-332.
34. Van Rensburg, S.J., Cook-Mozaffari, P., Van Schalkwyk, D.J., Van der Watt, J.J., Vincent, T.J., and Purchase, L.F. 1985. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br. J. Cancer, 51: 713-726.
35. Wang, J.-S., Qian, G.-S., Zhu, Y.-R., Zarba, A., Munoz, A., Kensler, T.W., and Groopman, J.D. 1995. Temporal patterns and persistence of aflatoxin-albumin adducts in residents of Daxin Township, Qidong, P.R.C. Proc. Am. Assoc. Cancer Res. 36: 282.
36. Wild, C.P., Jiang, Y.Z., Sabbioni, G., Chapot, B., and Montesano, R. 1990a. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. Cancer Res. 50: 245-251.
37. Wild, C.P., Jiang, Y.Z., Allen, S.J., Jansen, L.A., Hall, A.J., and Montesano, R. 1990b. Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis, 11: 2271-2274.
38. Wild, C.P., Hudson, G., Sabbioni, G., Wogan, G.N., Whittle, H., Montesano, R., and Groopman, J.D. 1992. Correlation of dietary intake of aflatoxins with the level of albumin bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiology, Biomarkers and Prevention, 1: 229-234.
39. Yeh, F.-S., and Shen, K.-N. 1986. Epidemiology and early diagnosis of primary liver cancer in China. Adv. Cancer Res. 47: 297-329.
40. Yeh, F.-S., Yu, M.C., Mo, C., Luo, S., Tong, M.J., and Henderson, B.E. 1989. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res. 49: 2506-2509.